Month: February 2025

The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025) was held from February 13 to 15 in San Francisco, showcasing the latest research and treatment strategies in the field of urological oncology from experts worldwide. Several clinical research findings from Dr. Hongqian Guo’s team at Nanjing Drum Tower Hospital were selected for presentation, covering a wide range of topics, including non-clear cell renal cell carcinoma (nccRCC), small renal tumors, metastatic hormone-sensitive prostate cancer (mHSPC), upper tract urothelial carcinoma (UTUC), and bladder cancer. Urology Frontier invited Professors Xuefeng Qiu, Shun Zhang, Guangxiang Liu, Yifan Sun, and Dr. Xi Zheng from Nanjing Drum Tower Hospital to share their insights.

The NeoSTAR trial, published in March 2024, evaluated neoadjuvant sacituzumab govitecan (SG) in early-stage triple-negative breast cancer (TNBC). This study explored a response-guided approach using SG alone for four cycles.…

Currently, chemotherapy combined with immunotherapy for bladder preservation has met the clinical needs of some muscle-invasive bladder cancer (MIBC) patients, offering a potential balance between effective tumor control and improved quality of life. However, for MIBC patients who are intolerant to platinum-based chemotherapy, bladder-preserving strategies still require further exploration. At the recently held ASCO-GU Annual Meeting, Dr. Peng Zhang’s team from West China Hospital, Sichuan University, presented the HOPE series studies, among which the HOPE 03 study showcased the efficacy of ADC combined with immunotherapy in bladder preservation for MIBC patients. Urology Frontier invited Professor Zhang to share the key highlights of this research.

Clear cell renal cell carcinoma (ccRCC) is widely associated with dysregulation of the VHL (Von Hippel-Lindau) pathway, leading to overexpression of HIF-2α, which activates multiple oncogenic pathways. Targeting HIF-2α, with therapies such as belzutifan, has brought new hope to VHL patients and renal cancer patients alike. At this year’s ASCO GU symposium, Urology Frontier invited Dr. Kan Gong from Peking University First Hospital to engage in a discussion with Dr. Eric Jonasch, Director of the VHL Clinical Center at MD Anderson Cancer Center. Together, they explored VHL disease characteristics, the mechanism of action of belzutifan, key research findings, and its clinical value.

The Phase II DORA study, published in April 2024, evaluated the efficacy of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer (aTNBC).…

Clear cell renal cell carcinoma (ccRCC) is closely associated with dysregulation of the VHL pathway, leading to the overexpression of HIF-2α and activation of multiple oncogenic pathways. Targeting HIF-2α with therapies such as belzutifan has provided new hope for patients with VHL syndrome and even broader applications in kidney cancer treatment. At this year’s ASCO Genitourinary Cancers Symposium (ASCO GU), Urology Frontier invited Dr. Kan Gong from Peking University First Hospital to discuss with Dr. Eric Jonasch, Director of the VHL Clinical Center at MD Anderson Cancer Center, the patient populations benefiting from belzutifan, management of adverse effects, and its future clinical applications.